Ja. Dan et A. Yaron, FOCAL SCLERAL PERMEABILITY ENHANCED BY COLLAGENASE DIGESTION - EXPERIMENTAL-MODEL OF ENZYMATIC SCLEROSTOMY, Ophthalmology, 101(3), 1994, pp. 461-472
Purpose: The purpose of this study is to demonstrate that restricted a
pplication of clostridial collagenase to the animal sclerolimbal area
produces increased tissue permeability in vitro and results in a lasti
ng significant decrease in the intraocular pressure (IOP) in vivo. Met
hods: A special miniature device was developed to apply the carefully
characterized enzyme to a small (l-mm diameter) and defined sclerolimb
al area isolated from the surrounding tissue. The device was applied t
o the rabbit limbus for 4 hours and then removed. The enzyme was inact
ivated and washed out with an inhibitory solution. The IOP was measure
d by pneumotonometry, and the treated tissue was investigated by light
and electron microscopy. Application and removal of the drug-delivery
microapplicator was performed under topical anesthesia. Results: Enzy
matic degradation propagated without lateral spreading and reached at
least two thirds of tissue width. Results of histologic examination of
the treated area showed a thin tissue, characterized by degraded and
disorganized collagen fibers, which were sharply separated from the in
tact fibers in the untreated area. This was sufficient to cause a tenf
old increase in the basic transscleral flow in vitro, and a significan
t, relatively long-lasting (> 30 days) lowering of the mean IOP in 15
albino rabbits. In the first IO-day period after treatment, the IOP wa
s reduced by 40%, and during the rest of the follow-up the IOP remaine
d lowered by more than 20% (P > 0.0001) without any adjuvant treatment
. Conclusion: Despite the small size of the collagenase-affected tissu
e, the evacuation rate of the aqueous humor was sufficient to cause a
significant and relatively longlasting lowering of IOP in rabbits. Thi
s mild treatment, performed under topical anesthesia, might present th
e basis for the development of an ambulatory treatment of human glauco
ma.